A new retrospective claims analysis evaluated adherence to extended-release buprenorphine and its impact on healthcare resource utilization and cost among commercially insured patients with opioid use...
An open-label, randomized trial found that daratumumab and hyaluronidase-fihj administered subcutaneously improved the risk of disease progression or death in patients with multiple myeloma. As a result,...
In a large multicountry trial, researchers evaluated whether an integrase inhibitor–based regimen offers comparable or superior treatment outcomes to a boosted protease inhibitor regimen in adults with...
In a recent presentation at Practical Updates in Primary Care, Joel M. Gelfand, MD, provided an overview of psoriasis care for primary care providers alongside co-presenter Annie Truss, MD. In this...
The Consultant360 Multidisciplinary Roundtable on the September 2025 ACIP (Advisory Committee on Immunization Practices) updates brought together leading vaccine experts—including Drs Bonnie Maldonado, Art...
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
The November issue of Consultant brings together a diverse collection of case reports, from rare vascular emergencies to transplant-related complications and persistent hip pain following a fall. With each...
In this episode of Ask the Experts, dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares what's unique about the formulations of ZORYVE® (roflumilast). Mr. DiRuggiero discusses how...
A 50-year-old man presented to the emergency department (ED) after slipping on a wet stone surface while fishing at a beer festival. He presents with altered mental status and a vague symptom of headache.
...
Jay Talati, MD; Kevin Pierre, MD; Gia Serrano; Chase Labiste, MD; Jeffrey Vogel, MD; Hugh Davis, MD
A 52-year-old woman with a history of kidney and pancreas transplantation (17 years prior), end-stage renal disease on dialysis, type 1 diabetes mellitus, hypertension, and class 2 pulmonary hypertension...
Advanced or recurrent endometrial cancer has long meant limited paths forward. But that may be changing. In this short video, two experts share compelling phase 3 data on a treatment option and what it could mean for real-world care.
